Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDSonoma Pharmaceuticals, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$3.41 | -$3.41 | -$3.41 |
| Q2 2024 | 1 | -$1.00 | -$1.00 | -$1.00 |
| Q3 2024 | 1 | -$0.80 | -$0.80 | -$0.80 |
| Q4 2024 | 1 | -$0.69 | -$0.69 | -$0.69 |
| Q1 2025 | 1 | -$0.73 | -$0.73 | -$0.73 |
| Q2 2025 | 1 | -$0.62 | -$0.62 | -$0.62 |
| Q3 2025 | 1 | -$0.37 | -$0.37 | -$0.37 |
| Q4 2025 | 1 | -$0.39 | -$0.39 | -$0.39 |
| Q1 2026 | 1 | -$0.43 | -$0.43 | -$0.43 |
Sonoma Pharmaceuticals, Inc. Earnings Date And Information
Sonoma Pharmaceuticals, Inc. last posted its earnings results on Thursday, November 7th, 2024. The company reported $-0.59 earnings per share for the quarter, topping analysts' consensus estimates of $-1 by $0.41. The company had revenue of 3.58 M for the quarter and had revenue of 12.74 M for the year. Sonoma Pharmaceuticals, Inc. has generated $-11 earnings per share over the last year ($-10.64 diluted earnings per share) and currently has a price-to-earnings ratio of -0.77. Sonoma Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 6th, 2025 based on prior year's report dates.
Sonoma Pharmaceuticals, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/07/2024 | Q2 2025 | -$1.00 | -$0.59 | 0.41 | $3.82 M | $3.58 M |
| 08/08/2024 | Q1 2025 | -$0.06 | -$1.34 | -1.28 | $3.78 M | $3.39 M |
| 06/17/2024 | Q4 2024 | -$1.37 | $3.44 M | |||
| 02/08/2024 | Q3 2024 | -$1.59 | $3.14 M | |||
| 11/13/2023 | Q2 2024 | -$0.24 | -$5.80 | -5.56 | $3.60 M | $2.73 M |
| 08/10/2023 | Q1 2024 | -$5.80 | $3.38 M | $3.43 M | ||
| 06/21/2023 | Q4 2023 | -$5.60 | $3.01 M | |||
| 02/14/2023 | Q3 2023 | -$12.40 | $2.94 M | |||
| 11/14/2022 | Q2 2023 | -$6.60 | $3.33 M | |||
| 08/11/2022 | Q1 2023 | -$5.80 | $3.98 M | |||
| 07/13/2022 | Q4 2022 | -$22.20 | $2.30 M | |||
| 02/11/2022 | Q3 2022 | -$6.20 | $2.90 M | |||
| 11/15/2021 | Q2 2022 | -$0.85 | $3.74 M | |||
| 08/16/2021 | Q1 2022 | -$10.40 | $3.68 M | |||
| 07/14/2021 | Q4 2021 | -$35.60 | $2.16 M | |||
| 02/16/2021 | Q3 2021 | -$6.40 | $4.94 M | |||
| 11/20/2020 | Q2 2021 | $1.20 | $5.77 M | |||
| 08/14/2020 | Q1 2021 | $2.60 | $7.25 M | |||
| 07/10/2020 | Q4 2020 | -$15.40 | $4.58 M | |||
| 02/14/2020 | Q3 2020 | -$14.40 | $4.68 M |
Sonoma Pharmaceuticals, Inc. Earnings: FAQ's
When is Sonoma Pharmaceuticals, Inc.'s earnings date?
Sonoma Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 6th, 2025 based off last year's report dates.
Did Sonoma Pharmaceuticals, Inc. beat their earnings estimates last
quarter?
In the previous quarter, Sonoma Pharmaceuticals, Inc. (:SNOA) reported $-0.59 earnings per share (EPS) to beat the analysts' consensus estimate of $-1 by $0.41.
How can I listen to Sonoma Pharmaceuticals, Inc.'s earnings conference
call?
The conference call for Sonoma Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
How can I read Sonoma Pharmaceuticals, Inc.'s conference call transcript?
The conference call transcript for Sonoma Pharmaceuticals, Inc.'s latest earnings report can be read online.
How much revenue does Sonoma Pharmaceuticals, Inc. generate each year?
Sonoma Pharmaceuticals, Inc. (:SNOA) has a recorded annual revenue of $12.74 M.
How much profit does Sonoma Pharmaceuticals, Inc. generate each year?
Sonoma Pharmaceuticals, Inc. (:SNOA) has a recorded net income of $12.74 M. Sonoma Pharmaceuticals, Inc. has generated $-10.64 earnings per share over the last four quarters.
What is Sonoma Pharmaceuticals, Inc.'s price-to-earnings ratio?
Sonoma Pharmaceuticals, Inc. (:SNOA) has a price-to-earnings ratio of -0.77 and price/earnings-to-growth ratio is -0.01.